SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 02, 2025--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other most profitable biotech stocks to buy right now. With improved market ...

United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million.

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against ...

Received FDA authorization and recorded first commercial sales of ARC-EX SystemSecured strategic investment from Ottobock and extended cash ...

Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...

In the first quarter of 2025, ONWARD Medical reported a significant increase in revenue, driven by strategic innovations and market expansion. Despite posting a net loss, the company’s stock price ...

Drug developers will now have enhanced abilities to rapidly prototype, test, iterate, and scale up their mRNA therapeutics.

Announced the acceptance of the New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for OLC for the treatment of hyperphosphatemia in patients with CKD on dialysis. The FDA set a ...

Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...